Mol Med Rep 16: [Related article:] 673-679, 2017; DOI:
10.3892/mmr.2017.6643
Following the publication of this article, an
interested reader drew to our attention that we had incorrectly
reported (in the Materials and methods section, ‘Western blot
analysis’, on p. 674) that the anti-farnesoid X receptor (FXR)
antibody of Cell Signalling Technology, Inc., cat. no. #12295, had
been used in this study to probe for FXR. In fact, the antibodies
used in the above-mentioned study were a gift from the group of Dr
Xin-Liang Ma at Thomas Jefferson University (Philadelphia, PA,
USA), as referenced in the following article: [Pul J, Yuan A, Shan
P, Gao E, Wang X, Wang Y, Lau WB, Koch W, Xin-Ma XL and He B:
Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis
mediator and contributes to myocardial ischaemia/reperfusion
injury. Eur Heart J 34: 1834–1845, 2013]. The antibody that was
used for the western blotting analysis was raised against the
C-terminus of FXR (C-20; cat. no. sc-1204, Santa Cruz
Biotechnology, San Diego, CA, USA).
We sincerely apologize for this mistake, and thank
the reader of our article who drew this matter to our attention.
The error made in our incorrect referencing of the antibody did not
affect the conclusions reported in this study. Furthermore, we
regret the inconvenience that this mistake caused.
